Belldegrun Arie
Belldegrun Arie's purchase track record
Belldegrun Arie has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/16/2024 | ALLO | $5.00M | -23.6% | -18.3% | +12.3% |
| 1/12/2022 | ALLO | $1.95M | -28.9% | -0.7% | -19.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value. Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
Transaction History
| ALLO | ▲ Buy | Grant | 369,957 | $0 | 1/24/2025 | View on chart |
| DNA | ▲ Buy | Option Exercise | 105,263 | — | 6/12/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 344,828 | $1.0M | 5/16/2024 | View on chart |
| ALLO | ▲ Buy | Open Market | 1,724,137 | $5.0M | 5/16/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 211,973 | $0 | 1/25/2024 | View on chart |
| ALLO | ▲ Buy | Grant | 1,282,976 | $0 | 3/22/2023 | View on chart |
| URGN | ▲ Buy | Option Exercise | 160,000 | $800K | 9/14/2022 | View on chart |
| URGN | ▲ Buy | Option Exercise | 3,241 | $16K | 8/31/2022 | View on chart |
| DNA | ▲ Buy | Grant | 70,921 | $0 | 6/10/2022 | View on chart |
| ALLO | ▼ Sell | Other | 4,710,121 | $0 | 3/14/2022 | View on chart |
| ALLO | ▼ Sell | Other | 4,710,121 | $0 | 3/14/2022 | View on chart |
| ALLO | ▲ Buy | Open Market | 155,039 | $2.0M | 1/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns
Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.